Fusion Pharmaceuticals
As of the edition of 20 October 2026, Fusion Pharmaceuticals runs 7 drugs; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Fusion Pharmaceuticals was acquired in 2024.
- Fusion Pharmaceuticals Inc.: acquired in 2024
Drugs by status
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 1 |
| Stopped | 3 |
| Status not established | 2 |
| Total | 7 |
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| FGFR3 Fibroblast growth factor receptor 3 | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Fusion Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 3 trials led
- Hormones: 2 trials led
- Pregnancy and women's health: 2 trials led